



LASA SUPERGENERICS LIMITED

Corporate Office : Office No . 705, Minerva Estate, Asha Nagar A Wing, O2 Commercial Tower,
Mulund (West) , Mumbai- 400 080

Email : info@lasalabs.com • Website : www.lasalabs.com

Ref. No.: LASA/SE/21-22/46
Wednesday March 09, 2022

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Sub: Press Release

Dear Sir/Madam,

Attached is the copy of Press Release titled “**LASA FILES ANOTHER SUIT FOR PERMANENT INJUNCTION AGAINST ONE OF ITS COMPETITOR**” issued by the Company.

You are requested to note the above on your records.

Thanking You.

Yours faithfully,

FOR LASA SUPERGENERICS LIMITED



ANKITA SHETTY
COMPANY SECRETARY AND COMPLIANCE OFFICER
ENCL: AS ABOVE

CIN : L24233MH2016PLC274202



Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

Lasa files another Suit for permanent injunction against one of its competitors.

Mumbai, March 09, 2022 Lasa Supergenerics Limited, India's Leading API Manufacturer, announced that it has filed suit for permanent injunction restraining infringement of its patent.

Lasa Supergenerics Limited (herein referred to as Lasa) has filed a suit for Permanent injunction restraining infringement of its Patent, Tortious interference, Confidential Breach and Misuse of information, unfair trading etc. rendition of accounts and damages in respect of **Indian Patent no. 326628** in respect of an invention titled **“AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5 (PROPYLTHIO)-1H-BENZO [D] IMIDAZOL-2-YLCARBAMATE”**, which protects the process for manufacture of a product named **Albendazole**, filing aimed to prevent the unauthorised use and disclosure of the confidential information owned by Lasa, to prevent the acts of interference in the business activities, to prevent interference in contractual obligations, to prevent the inducement and incitement to the contractual employees, unfair trading before the Commercial Division of the Hon'ble Bombay High Court against **Lohita Lifescience Pvt Ltd and others**.

Commenting on this development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics said:

This could be yet another milestone for Lasa, as it may restrain its competitors from manufacturing and dealing in one of the key product and enables the company to continue its leadership for its key products worldwide.

We continue to keep close watch against offenders and are prepared to fully approach relevant authorities so that to keep our market share sustained.



Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

Further Lasa is also seeking ad interim and interim reliefs pending the hearing and final disposal of the suit and claiming an amount of Rs. 3,00,00,00,000/- (Rupees Three hundred crores only) as compensation for loss of business opportunity and customer at large scale globally.

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Founded in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

For any Investor Relations query, please contact:

Ms. Ankita Shetty
Lasa Supergenerics Limited

Email: cs@lasalabs.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue*



Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

